WORLD CB AND CDX BOSTON 2019 (CLINICAL BIOMARKER AND COMPANION DIAGNOSTICS)September 9-12, 2019 The Renaissance Boston Waterfront, Boston, MA Flagship Biosciences is a proud Spotlight Partner of World CB and CDx Boston 2019. Flagship’s leaders will be speaking and...
Sign up to receive industry and company news, including The Cut Point, Flagship’s quarterly e-newsletter.
NEWS
Dr. Roberto Gianani and Michael Koratich Named to Key Medical and Pharma RolesWestminster, CO – March 10, 2021 – Flagship Biosciences, the leader in data-centric pathology and tissue analysis, today announced strategic additions to its executive team. Dr. Roberto...
Patent Number 10,839,512 Issued for New Tissue Sample Image Dot Detection MethodWestminster, CO – February 17, 2021 – Flagship Biosciences, the leader in data-centric pathology tissue analysis, today announced that the United States Patent and Trademark Office has...
The new technical partnership between Inspirata and Flagship Biosciences provides clinicians with a seamless, fully automated AI send-out solution, offering significant advantages over standard material transfers.Tampa, FL and Westminster, CO – (Globe Newswire)...
PUBLICATIONS/POSTERS
CIOReview named Flagship Biosciences “Company of the Year,” as part of the publication’s 2018 20 Most Promising Pharma & Life Sciences Tech Solution Providers industry review. “The ease of leveraging Flagship’s powerful solution is yet another massive...
Key Concepts: Pathological interpretations applied to PD-L1 IHC as a response biomarker are becoming more complex, going beyond simple tumor proportion score (TPS) and requiring more complex diagnostic algorithms that evaluate the role of PDL1 expression in tumor...
Key takeways: Successful pathology AI does not replace, but assist pathologists in high-complexity tissue analysis Transparency and control is retained in a pathologist-centric AI-based system Pathology AI enables cost effective healthcare by testing for multiple...